Mon, Mar 2, 2026|Chris Igou

China's Beauty Obsession Is Creating a Pharma Opportunity

This essay was originally published in DailyWealth Trader, a daily trading advisory, and has been adapted. To learn more about this service, click here.

If you think American beauty standards are exacting, China's are on another level...

A few years ago, a social media trend went viral that typified Chinese "glamor." Westerners know it as the "fish in collarbone challenge"...

Women would pour water into the empty space behind their collarbone. Then, they'd place a small fish in the pooled liquid. To "pass," your collarbone had to hold enough water for the fish to swim.

Now, I'm neither endorsing nor encouraging the challenge. It enforces an unrealistic beauty standard for women. (And it's probably not great for the fish, either.)

But there's a key investment fact lurking behind this controversial trend. Let me explain...

The Obesity-Drug Boom Is Going Global

Over the past several years, the fish in collarbone challenge has appeared on social media from time to time. It's a little easier to understand with a visual...

A challenge like this shows the extremely high standards for what constitutes "thinness" in China. That tells us that China is just as weight-obsessed as we are, if not more so.

This is a key concept for investors to grasp... because today, obesity pills are making new inroads in Beijing. That's a big boost for the obesity-drug market.

And U.S. pharma giant Pfizer (PFE) is making a bid for that market in China...

Last week, Bloomberg reported that Pfizer gained exclusive rights to sell weight-loss therapies on the Chinese mainland. It will partner with Chinese pharmaceutical company Hangzhou Sciwind Biosciences to commercialize a new GLP-1 injectable called Ecnoglutide.

Sciwind Biosciences will research, develop, manufacture, and supply the drug locally. Plus, the company will receive up to $495 million in the deal.

Pfizer will retain commercialization rights on the drug – allowing it to market, sell, and distribute the drug across China.

This is a strategic expansion for Pfizer. About 14.1% of Chinese adults are obese. And there's a lot of money on the table.

This marriage with Sciwind Biosciences could be a major tailwind for Pfizer. The company is already seeing renewed interest as it stakes its claim in China...

We can see it by looking at Pfizer's 200-day moving average (200-DMA). We use the 200-DMA because it smooths out daily volatility to show the prevailing trend. And because it moves so slow, the 200-DMA acts as a long-term trend line.

When the moving average is falling, the stock is trending lower. When it's flat, the stock is grinding sideways. And when it's rising, a new uptrend is underway.

After months of drifting lower or sideways, Pfizer's 200-DMA is finally starting to rise. Take a look...

This shift in the long-term trend is highly bullish for Pfizer. And its new presence in China gives us the catalyst for a new leg higher.

The pharma giant is jumping into the thick of China's intense beauty culture. And its long-term trend shows that Mr. Market is starting to cheer along.

Good investing,

Chris Igou

China's Beauty Obsession Is Creating a Pharma Opportunity

The Obesity-Drug Boom Is Going Global

Further Reading

Recent Articles